nivolumab,ipilimumab
bms
['melanoma', 'nivo']
os results of resected stage iv melanoma treated in immuned phii trial were presented: clinically relevant but not statistically significant improvement of os of nivo+ipi vs nivo is shown. rfs benefit is maintained during fup #esmo22 #melanoma 
Medical Oncologist. Melanoma and Skin Tumors. Early phase and phase III clinical trials. Hospital Clínic (Barcelona). Opinions are mine.